Each patient in the GLP-1RA group was matched to 1 or more (at most 4) counterparts in the DPP-4i group
The in vitro ASBT binding cellular disposition was analyzed and a Caco-2 permeability assay was performed to evaluate cellular absorption
Shortness of breath, or dyspnea, is not listed as a common or characteristic adverse effect of GLP-1 receptor agonists in FDA-approved prescribing information
Our commitment to non-GMO, organic, and wild-crafted sourcing ensures that your routine is as clean as it is effective
Our state-of-the-art facilities and commitment to patient-centered care ensure that you receive the highest quality treatment and support throughout your journey.
Instead of separating costs for consultations, medication, and support, pricing is presented clearly upfront, making it easier to understand and plan for ongoing care